Follow the Camurus AB share price and the full directors' dealings record of the company, a listed issuer based in Finland. Shares trade on the FI market, under the supervision of FIN-FSA. Operating in the Health Care sector, Camurus AB has recorded 13 public disclosures. Market capitalisation: €37.6bn. The latest transaction was disclosed on 19 February 2026 (Purchase). Among the most active insiders: Fredrik Tiberg. All data is accessible without an account.
13
Insider Decl.
n/a
Thresholds
€63,042
2 ops.
Buy Volume
€2m
3 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Camurus AB Strong Buy (bullish), based on 8 analysts. Average price target: SEK 776.75.
37Σ signal
Buys €63,042€2m Sells
Fundamental score
Ranked 8,503 of 29,063 companies
61.9
score / 100
Value
34
Quality
90
FCF yld2.0%
Earn yld2.0%
EV/EBITDA38.2x
ROE16%
Gross mgn93%
Net mgn32%
Debt/EBITDA0.1x
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Σ
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
Camurus AB es una empresa biofarmacéutica sueca centrada en el desarrollo de tratamientos innovadores para enfermedades crónicas. Cotiza en la Bolsa de Estocolmo (XSTO).